ClinicalTrials.gg
CompletedNCT07428915LegitHealth BIUpdated Feb 24, 2026

Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists

An observational study in Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP) and Eczema Atopic Dermatitis, sponsored by AI Labs Group S.L. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by AI Labs Group S.L · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions. Dermatological issues are common in primary care, but there is often a gap in diagnostic accuracy between general practitioners and specialists, which can lead to treatment delays for serious conditions like Generalized Pustular Psoriasis (GPP) and Hidradenitis Suppurativa (HS).

The researchers hypothesized that the AI device would enhance the diagnostic accuracy of healthcare professionals for GPP and other dermatological conditions. To test this, the study followed a prospective observational design involving 15 practitioners, including both general practitioners and dermatologists.

During the study, participants were asked to evaluate 100 clinical images. For each case, they first provided a diagnosis based on the image and patient history alone. They were then shown the AI's analysis-which included the top five suggested diagnoses and confidence levels-and asked if they would like to adjust their initial assessment.

The primary question the study sought to answer was whether the information provided by the AI device could significantly increase the number of correct diagnoses made by these professionals, particularly for rare diseases that are often difficult to identify in a standard clinical setting

Read the detailed description

This investigation is structured as a multi-reader multi-case (MRMC) study. A cohort of 15 healthcare professionals, including 11 primary care physicians and 4 dermatologists, acted as the "readers". These readers evaluated a "case" set of 100 clinical images to assess diagnostic performance both with and without the assistance of the AI device.

Study Design and Technical Methodology The research was conducted as a prospective observational and cross-sectional study. It utilized a "physician-as-their-own-control" design to measure the impact of Artificial Intelligence (AI) on diagnostic performance.

  • Intervention Workflow: Participants accessed a dedicated web platform where they were presented with 100 clinical cases.
  • Evaluation Steps: For each case, practitioners first evaluated a clinical image alongside anamnesis data (e.g., allergies, systemic symptoms) to provide an initial diagnosis.
  • AI Support: Subsequently, they were presented with the AI's top 5 suggested diagnoses and associated confidence levels before making a final assessment.
  • Image Sourcing: Cases consisted of high-quality images of Generalized Pustular Psoriasis (GPP), Hidradenitis Suppurativa (HS), and various differential "look-alike" conditions such as subcorneal pustular dermatosis and palmoplantar pustulosis.
  • Data Sources: These images were curated from public dermatology atlases and internal research databases from the sponsor.

Quality Assurance and Data Management

To ensure the scientific integrity and reliability of the findings, several quality control measures were implemented:

  • Data Validation: A validation process of the clinical data was carried out by running computer filters based on validation rules.
  • Error Detection: These filters automatically identify missing values or inconsistencies. This was supplemented by manual editing and exploratory statistical techniques to detect logical errors and inconsistencies.
  • Monitoring Plan: The investigation was overseen by a designated clinical monitor appointed by the sponsor.
  • Remote Supervision: Monitoring activities included remote meetings every three months to review study progress and ensure ongoing compliance.
  • Bias Minimization: Random selection of healthcare professionals (HCPs) was used to ensure that outcomes were not influenced by pre-existing participant characteristics.
  • Standardization: The use of standardized procedures ensured that all participants were evaluated in the same way.

Statistical Analysis Plan

The primary goal of the analysis was to quantify Top-1 accuracy, sensitivity, and specificity for both general practitioners and dermatologists.

  • Comparative Metrics: The analysis focused on the absolute metric values compared against the state of the art, as well as the percentage of variation attributable specifically to the use of the device.
  • Subgroup Analysis: A dedicated analysis was performed for rare diseases, including GPP, Acne Conglobata, and Pemphigus Vulgaris, to assess the device's utility in high-complexity, low-incidence conditions.

Ethical and Confidentiality Framework The study adhered to UNE-EN ISO 14155:2021, the Declaration of Helsinki, and the General Data Protection Regulation (GDPR).

  • Anonymization: No data enabling the personal identification of participants or patients was collected.
  • Encryption: All information was managed securely in an encrypted format.
  • End of Study: All information stored in the device will be totally and permanently deleted at the end of the study.
02

Conditions studied

  • Pustular Psoriasis (PP)
  • Generalized Pustular Psoriasis (GPP)
  • Eczema Atopic Dermatitis
  • Acute Generalized Exanthematous Pustulosis
  • Acne
  • Acne Conglobata
  • Seborrheic Keratoses
  • Seborrheic Dermatitis
  • Palmoplantar Pustulosis
  • Plaque Psoriasis
  • Pemphigus Vulgaris (PV)
  • Impetigo
  • Hidradenitis Suppurativa (HS)
  • Tinea Corporis

Keywords

  • Generalized Pustular Psoriasis
  • Dermatologists
  • Primary Care Physicians
  • Rare diseases
  • Skin conditions
03

In context

Psoriasis

2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.

This study's enrollment of 15 is below the median of 199 across 407 observational studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

AI Labs Group S.L is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of board-certified healthcare professionals recruited from the clinical fields of general medicine and dermatology. The participant group includes:

  • Primary Care Practitioners: General practitioners who often serve as the first point of contact for patients with dermatological symptoms.
  • Specialist Dermatologists: Physicians with advanced expertise in skin pathologies and rare conditions.
  • Experience Level: The cohort includes practitioners with at least 5 years of clinical experience in their respective specialities.

Participants were recruited to engage in a remote, web-based evaluation environment rather than being selected from a single physical hospital or town. The clinical images evaluated as part of the study "cases" were sourced from international public dermatology atlases and existing research databases from the sponsor, representing a diverse global patient population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Board-certified general practitioners and dermatologists, regardless of their professional experience.
  • Good quality images of patients with GPP.
  • Good quality images of patients with HS.
  • Good quality images of patients with pathologies that can be confused with GPP or HS, leading to a wrong diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Images of patients with pathologies different from GPP or HS that can be easily identified.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
15 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthcare Professionals (Primary Care Physicians and Dermatologists)

    This group is composed of board-certified healthcare professionals (HCPs) who serve as the "readers" in this multi-reader multi-case (MRMC) study. The cohort is uniquely characterized by its internal comparison: each participant acts as their own control. * Dual Professional Roles: The group includes 11 primary care physicians (PCPs) and 4 dermatologists, allowing for a comparison between generalist and specialist diagnostic baseline performance. * Interventional Exposure: All participants are evaluated under two distinct conditions: first, providing a diagnosis based solely on clinical images and patient history; second, providing a diagnosis assisted by the AI-based medical device's top 5 suggestions and confidence levels. * Clinical Expertise: Every member of the cohort has a minimum of 5 years of clinical experience in their respective field.

    Device: AI-based medical device for aided diagnosis in Dermatology

Interventions

  • DeviceAI-based medical device for aided diagnosis in Dermatology

    The intervention consists of a Computer-Aided Diagnosis (CAD) software-only medical device that utilizes computer vision algorithms to analyze digital images of skin structures. During the study, healthcare professionals use the tool as a diagnostic support system to assist in the evaluation of complex dermatological conditions.

06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy for Generalized Pustular Psoriasis (GPP) with and without Artificial Intelligence Support.

    This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying GPP. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.

    Time frame: Day 1

  2. Diagnostic Accuracy for different skin conditions with and without Artificial Intelligence Support

    This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying the corresponding skin condition. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.

    Time frame: Day 1

Secondary outcomes

  1. Diagnostic Accuracy for Rare Dermatological Conditions with and without Artificial Intelligence Support.

    This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying rare dermatological conditions. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.

    Time frame: Day 1

07

Study locations

1 site
  • AI Labs Group S.L.
    Bilbao, Basque Country, Spain
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Sep 2024, 3 months.

Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's 3 months is below that.

Counting every sponsor, half of 173 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Jun 1, 2024
Primary completionActual
Sep 15, 2024
CompletionActual
Sep 15, 2024
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07428915
Lead sponsor
AI Labs Group S.L
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Jun 1, 2024
Primary completion
Sep 15, 2024
Completion
Sep 15, 2024
Last update
Feb 24, 2026

Study contacts

Antonio Martorell, PhD
principal investigator · Hospital Universitari de Manises

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion